Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119418 | 0.85 | KMT2A (0.44) | ALDH1A1KDM4EMAPTTSHRMAPK1 | |
| SCHEMBL5119412 | 0.85 | KMT2A (0.44) | ALDH1A1KDM4EMAPTTSHRMAPK1 | |
| SCHEMBL5115893 | 0.82 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1OXTRSMN1; SMN2NPC1 | |
| SCHEMBL5111729 | 0.82 | NPC1 (0.49) | HRH3ALDH1A1KDM4EMAPK1KMT2A | |
| SCHEMBL5507817 | 0.81 | L3MBTL1 (0.51) | HRH3ALDH1A1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL5118837 | 0.78 | L3MBTL1 (0.43) | HRH3KDM4EKMT2AL3MBTL1DRD4 | |
| SCHEMBL5112122 | 0.78 | CHRM1 (0.46) | HRH3KDM4EMAPK1KMT2AL3MBTL1 | |
| SCHEMBL27709208 | 0.78 | RAB9A (0.40) | HRH3ALDH1A1MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL3178297 | 0.77 | PDK2 (0.41) | ALDH1A1MAPTMAPK1KMT2AL3MBTL1 | |
| SCHEMBL5504494 | 0.75 | HRH3 (0.43) | HRH3ALDH1A1KDM4EMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | claimed |
| CN-101128460-A | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | claimed |
| US-20060148823-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | claimed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | COATS STEVEN J | 2008-12-25 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| US-7432257-B2 | Piperdinyl-phenoxazine and phenothiazine derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| CN-101128460-A | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-20 | — | — | CN | disclosed |
| US-20060148823-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148823-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | HRH3 736/4885ALDH1A1 1302/4885KDM4E 2174/4885 |
| US-20080318937-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | OPRD1, OPRK1, OPRL1 | HRH3 736/4885ALDH1A1 1302/4885KDM4E 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.